Compare Adaptive Biotechnologies Corp (ADPT) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs TORM plc — how do they compare? Adaptive Biotechnologies Corp trades at $24.96 (market cap $4.04B), while TORM plc trades at $28.77 (market cap $2.93B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and TORM plc pays a 9.77% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | TRMD | |
|---|---|---|
Market Cap | $4.04B | $2.93B |
Sector | Health | Technology |
52-Week High | $25.45 | $34.87 |
52-Week Low | $12.30 | $18.77 |
Enterprise Value | $4.10B | $3.82B |
Dividend Yield | — | 9.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
TRMD trades at $29.04, down 0.51% today, with a bearish technical signal from moving averages but oversold RSI at 24.63. The company reported strong profitability with a 24.41% net margin and ROE of 15.62%, though Q1 2026 EPS missed expectations. Recent news highlights a major shareholder update from Oaktree Capital and a $0.70 dividend payment scheduled for June 2026.
Outlook remains positive with 100% analyst buy ratings, underpinned by robust cash flow and strategic positioning in tanker markets. Risks include earnings volatility and geopolitical impacts on freight rates, but valuation metrics like P/E of 8.4 suggest potential upside if operational execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
